https://www.selleckchem.com/products/mki-1.html
INTRODUCTION Cytotoxic agents have immunomodulatory effects, providing rationale for combining atezolizumab (anti-programmed death-ligand 1 [PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated atezolizumab with platinum-based chemotherapy in stage IV squamous non-small cell lung cancer (NSCLC). METHODS 1021 patients were randomized 111 to receive atezolizumab+carboplatin+paclitaxel (A+CP) (n=338), atezolizumab+carboplatin+nab-paclitaxel (A+CnP) (n=343), or carboplatin+nab-paclitaxel (CnP) (n=34 f
إعجاب
علق
شارك
